SCHEMBL1083708

SCHEMBL1083708

Cc1cc(-c2cccc(OC(F)(F)F)c2)cc(C)c1C(=O)N1CCC(N2CCC[C@H]2CO)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 1/20 0.42
SLC6A7 Q99884 1/20 0.41
USP30 Q70CQ3 1/20 0.41
HSD11B1 P28845 1/20 0.40
MGLL Q99685 2/20 0.40
DHODH Q02127 1/20 0.40
MAP3K7 O43318 1/20 0.39
TAB1 Q15750 1/20 0.39
CACNA1B Q00975 2/20 0.38
CHRM3 P20309 1/20 0.38
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
EPHX2 P34913 1/20 0.37
DGAT2 Q96PD7 1/20 0.37
MMP2 P08253 1/20 0.36
MMP3 P08254 1/20 0.36
PIM1 P11309 1/20 0.36
CSNK1E P49674 1/20 0.36
GHSR Q92847 1/20 0.36
MAPK7 Q13164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1085077 1.00 CCR5 (0.42) CCR5SLC6A7USP30HSD11B1MGLL
SCHEMBL1085279 0.90 EPHX2 (0.43) CCR5HSD11B1MGLLCHRM3EPHX2
SCHEMBL1083701 0.90 EPHX2 (0.43) CCR5HSD11B1MGLLCHRM3EPHX2
SCHEMBL1083695 0.88 ALDH1A1 (0.38) CCR5SLC6A7USP30HSD11B1MGLL
SCHEMBL1085293 0.88 ALDH1A1 (0.38) CCR5SLC6A7USP30HSD11B1MGLL
SCHEMBL1083706 0.86 TRPV1 (0.47) CCR5CHRM3
SCHEMBL1085174 0.86 TRPV1 (0.47) CCR5CHRM3
SCHEMBL1083700 0.84 L3MBTL3 (0.47) CCR5SLC6A7HSD11B1MGLLDHODH
SCHEMBL1085088 0.83 MAPK7 (0.41) SLC6A7HSD11B1MGLLMAP3K7TAB1
SCHEMBL1083744 0.83 MAPK7 (0.41) SLC6A7HSD11B1MGLLMAP3K7TAB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153805-B2 Biaryl derivatives HOFFMANN-LA ROCHE INC. (US) 2012-04-10 US disclosed
US-8153805-B2 Biaryl derivatives HOFFMANN-LA ROCHE INC. (US) 2012-04-10 US disclosed
US-8153805-B2 Biaryl derivatives HOFFMANN-LA ROCHE INC. (US) 2012-04-10 US disclosed
WO-2009043747-A2 N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-09 WO disclosed
US-20090048238-A1 NOVEL BIARYL DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-02-19 US disclosed
US-20090048238-A1 NOVEL BIARYL DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-02-19 US disclosed
US-20090048238-A1 NOVEL BIARYL DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048238-A1 NOVEL BIARYL DERIVATIVES CCR3, CCRL2, CCR2 CCR5 5/4885SLC6A7 1980/4885USP30 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.